Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncimmune Holdings PLC (GB:ONC)
LSE:ONC
Oncimmune Holdings (ONC) Share Price & Analysis
2 Followers
ONC Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range9.75p - 31.00p
Previous Close9.85p
Volume280.09K
Average Volume (3M)82.91K
Market Cap
£7.30M
Enterprise Value9.40M
Total Cash (Recent Filing)£3.21M
Total Debt (Recent Filing)£5.30M
Price to Earnings (P/E)1.1
Beta0.99
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding74,142,147
10 Day Avg. Volume60,883
30 Day Avg. Volume82,911
Standard Deviation0.19
R-Squared0.00633
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-2.45
Price to Sales (P/S)443528.91
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Oncimmune Holdings News
PremiumCompany Announcements
Spreadex Adjusts Stake in Oncimmune Holdings
PremiumCompany Announcements
Spreadex LTD Adjusts Stake in Oncimmune Holdings
PremiumCompany Announcements
Oncimmune Holdings Shareholding Shift by Spreadex LTD
PremiumCompany Announcements
Oncimmune Sees Revenue Growth and Strategic Gains
PremiumCompany Announcements
Oncimmune Holdings Unveils Upcoming Investor Presentation
PremiumCompany Announcements
Oncimmune Shareholder Structure ShiftsPremiumCompany Announcements
Oncimmune Enhances Brokerage Team for Precision Medicine
PremiumCompany Announcements
Spreadex Adjusts Stake in Oncimmune HoldingsOptions Prices
Currently, No data available
---
Ownership Overview
19.99% Insiders
<0.01% Mutual Funds
0.00% Other Institutional Investors
80.01% Public Companies and
Individual Investors
ONC FAQ
What was Oncimmune Holdings PLC’s price range in the past 12 months?
Oncimmune Holdings PLC lowest share price was 9.75p and its highest was 31.00p in the past 12 months.
What is Oncimmune Holdings PLC’s market cap?
Currently, no data Available
When is Oncimmune Holdings PLC’s upcoming earnings report date?
Oncimmune Holdings PLC’s upcoming earnings report date is Feb 27, 2025 which is in 235 days.
How were Oncimmune Holdings PLC’s earnings last quarter?
Oncimmune Holdings PLC released its earnings results on May 21, 2024. The company reported 0.11p earnings per share for the quarter, beating the consensus estimate of N/A by 0.11p.
Is Oncimmune Holdings PLC overvalued?
According to Wall Street analysts Oncimmune Holdings PLC’s price is currently Overvalued.
Does Oncimmune Holdings PLC pay dividends?
Oncimmune Holdings PLC does not currently pay dividends.
What is Oncimmune Holdings PLC’s EPS estimate?
Oncimmune Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncimmune Holdings PLC have?
Oncimmune Holdings PLC has 74,142,140 shares outstanding.
What happened to Oncimmune Holdings PLC’s price movement after its last earnings report?
Oncimmune Holdings PLC reported an EPS of 0.11p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.811%.
Which hedge fund is a major shareholder of Oncimmune Holdings PLC?
Currently, no hedge funds are holding shares in GB:ONC
---
Oncimmune Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.50%
Trailing 12-Months
Company Description
Oncimmune Holdings PLC
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes EarlyCDT and ImmunoINSIGHTS. It generates maximum revenue from the EarlyCDT segment.
---
Technical Analysis
---